Compare Incyte Corporation (INCY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ulta Beauty Inc — how do they compare? Incyte Corporation trades at $113.79 (market cap $22.85B), while Ulta Beauty Inc trades at $570.31 (market cap $24.12B). The key difference: Incyte Corporation and Ulta Beauty Inc are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Ulta Beauty Inc for 92 Days on average.
| INCY | ULTA | |
|---|---|---|
Market Cap | $22.85B | $24.12B |
Volume | 1,927,029 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $706.82 |
52-Week Low | $83.80 | $450.75 |
Typical Hold Time | 33 Days | 92 Days |
Enterprise Value | $18.35B | $26.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
ULTA Beauty trades at $570.02, up 4.5% today, showing strong momentum with a bullish technical setup and positive analyst sentiment. The company delivered Q2 2026 earnings beat ($6.55 actual vs. $6.22 expected) and raised 2026 guidance, supported by robust e-commerce growth. Valuation metrics show a P/E of 20.55 and P/S of 1.92, while profitability remains solid with 39.3% gross margins and 46.1% ROE. Recent news highlights expansion into wellness categories and omnichannel strength.
Outlook remains positive with consensus price target of $624.93 (9.6% upside), though margin pressure and flat store traffic pose execution risks. The stock's current price near resistance at $572 suggests potential near-term consolidation before further gains. Institutional ownership trends show mixed activity with recent CEO share sales offset by pension fund accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
